Sugi Predict

Sugi Predict / Compounds / SCHEMBL611770

SCHEMBL611770

SCHEMBL611770

CC(C)N1CCN(c2ccc([N+](=O)[O-])nc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.67
▸ POLB P06746 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.58
▸ RAB9A P51151 1/20 0.56
▸ CHRNB2 P17787 3/20 0.50
▸ CHRNA4 P43681 3/20 0.50
▸ CHRNB4 P30926 2/20 0.50
▸ CHRNA3 P32297 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HRH3 Q9Y5N1 3/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.41
▸ TGM2 P21980 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521907 0.84 MAPT (0.72) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL29437382 0.82 MAPT (0.62) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL2722722 0.82 MAPT (0.62) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL29435521 0.82 MAPT (0.97) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL15141576 0.82 MAPT (0.97) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL3539759 0.82 MAPT (0.90) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL2401634 0.81 MAPT (0.60) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL19748624 0.81 MAPT (0.53) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL29437410 0.80 MAPT (1.00) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL2722856 0.80 MAPT (1.00) MAPTPOLBSMN1; SMN2RAB9ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325544-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-10-23 — — US disclosed
US-20250281487-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-11 — — US disclosed
US-20250275972-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-04 — — US disclosed
US-20250275971-A1 CDK INHIBITORS GENENTECH, INC. (US) 2025-09-04 — — US disclosed
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 — — CN disclosed
US-12285429-B2 CDK inhibitors GENENTECH, INC. (US) 2025-04-29 — — US disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20250064806-A1 CDK INHIBITORS GENENTECH, INC. 2025-02-27 — — US disclosed
US-8481540-B2 Inhibitors of bruton's tyrosine kinase HOFFMANN-LA ROCHE INC. (US) 2013-07-09 — — US disclosed
EP-2603500-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F.HOFFMANN-LA ROCHE AG (CH) 2013-06-19 — — EP disclosed
CN-103168039-A Imidazopyridine type SYK inhibitors GILEAD SCIENCES INC 2013-06-19 — — CN disclosed
CN-103153984-A Inhibitors of bruton's tyrosine kinase HOFFMANN LA ROCHE 2013-06-12 — — CN disclosed
EP-2545052-A1 IMIDAZOPYRIDINES SYK INHIBITORS Gilead Connecticut, Inc. (US) 2013-01-16 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed
WO-2012020008-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE F. HOFFMANN-LA ROCHE AG (CH) 2012-02-16 — — WO disclosed
US-20120040949-A1 Inhibitors of Bruton's Tyrosine Kinase BERTHEL STEVEN JOSEPH (US) 2012-02-16 — — US disclosed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO disclosed
WO-2011112995-A1 IMIDAZOPYRIDINES SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 MAPT 3872/4885POLB 139/4885SMN1; SMN2 3155/4885
US-20250281487-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 MAPT 2063/4885POLB 463/4885SMN1; SMN2 2041/4885
US-20250064806-A1 CDK INHIBITORS CDK9, CDK6, CDK3 MAPT 1865/4885POLB 390/4885SMN1; SMN2 2777/4885
US-12285429-B2 CDK inhibitors CDK9, CDK3, CDKL1 MAPT 2200/4885POLB 359/4885SMN1; SMN2 2470/4885
US-20250325544-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 MAPT 2063/4885POLB 463/4885SMN1; SMN2 2041/4885
US-20250275972-A1 CDK INHIBITORS CDK9, CDK6, CDK3 MAPT 1865/4885POLB 390/4885SMN1; SMN2 2777/4885
US-20120040949-A1 Inhibitors of Bruton's Tyrosine Kinase BTK, SYK, LYN MAPT 4109/4885POLB 2122/4885SMN1; SMN2 4068/4885
US-20250275971-A1 CDK INHIBITORS CDK6, CDK9, CDKL1 MAPT 2063/4885POLB 463/4885SMN1; SMN2 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.